What we're reading, June 29, 2016: CMS is considering changes to the proposed Medicare Part B demonstration; Senate Democrats block the GOP's Zika funding bill; and a Bloomberg analysis shines light on the pricing practices of the pharmaceutical industry.
A proposed change to Medicare Part B payment that has been met with some dissatisfaction from providers and patient groups could change in response to comments CMS received. According to The Wall Street Journal, Patrick Conway, MD, acting deputy administrator at CMS, said the agency is reviewing the more than 1300 public comments about the proposal and could alter the plan. Opponents to the proposal are concerned that it will limit seniors’ access to drugs. The proposed program would test changes to how providers are reimbursed for administering drugs in offices or outpatient settings.
Senate Democrats have blocked the GOP bill to fund the fight against the Zika virus. Democrats refused to pass the bill because Republicans had included in it provisions to deny new funding for Planned Parenthood clinics in Puerto Rico, reported AP. The legislation proposed funding of $1.1 billion, short of President Obama’s request of $1.9 billion. With the bill being blocked and Congress preparing for a 7-week vacation, it is unclear if a bill with funding to fight the virus will be passed.
In a special report, Bloomberg highlighted the secret drug pricing practices of the pharmaceutical industry. The analysis found even after estimated discounts are factored in, 30 of 39 medicines with global sales topping $1 billion a year had price increases that were more than double the rate of inflation from 2009 to 2015. Discounted prices for 27 drugs rose at rates of 25% or more compared with an increase of 9.5% for the consumer price index.
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Health Equity and Access Weekly Roundup: March 23, 2024
March 23rd 2024The Center on Health Equity and Access covered disparities in hypertension, diabetic eye health, and hidradenitis suppurativa, along with the proposed legislation banning diversity, equity, and inclusion efforts in Alabama schools and the consequences in sickle cell care from the CDC guideline for opioid prescriptions.
Read More
CMS is highly likely to negotiate the price of the obesity medication semaglutide in the coming years; many health care providers are trying to determine whether their cyberattack insurance will help cover their losses after the Change Healthcare hack; the US life expectancy increased for the first time in 2 years.
Read More